- Todos > Medicine Information and Evidence for Policy > Medicines Policy
- Todos > Medicine Access and Rational Use > Antimicrobial Drug Resistance
- Palabras clave > antibiotic resistance
- Palabras clave > antimicrobial resistance (AMR)
- Palabras clave > antimicrobials
- Palabras clave > pharmaceutical gaps
- Palabras clave > pharmaceutical innovation
- Palabras clave > pharmaceutical research - priorities
- Palabras clave > policy - priority issues
- Palabras clave > priority diseases
- Palabras clave > priority medicines
(2013; 122 pages)
The increasing prevalence of antimicrobial resistance (AMR) coupled with the dry antimicrobial development pipeline threatens the success and continuation of clinical medicine as we know it. This threat decreases the ability to successfully treat numerous infectious diseases while simultaneously increasing health risks for vulnerable patients. Medical procedures, such as hip replacements, organ transplants, chemotherapy, hemodialysis and care for preterm infants may become too risky or impossible due to untreatable community-acquired ("nosocomial") infections. Common infectious diseases may once again result in death.
The increased public health threats caused the World Health Organization (WHO) to declare AMR to be one of the three greatest threats to human health as reported for World Health Day 2011. In 2004, when the Priority Medicines for Europe and the World report was published, AMR was given great attention. This review together with annexes identifies what has occurred since 2004 to address this continuing challenge.